ZESTRIL Drug Patent Profile

Which patents cover Zestril, and when can generic versions of Zestril launch?

Zestril is a drug marketed by Twi Pharms and is included in one NDA.

The generic ingredient in ZESTRIL is lisinopril. There are twenty-one drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the lisinopril profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zestril

A generic version of ZESTRIL was approved as lisinopril by ASCENT PHARMS INC on July 1^st, 2002.

Summary for ZESTRIL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	23
Drug Prices:	Drug price information for ZESTRIL
Drug Sales Revenues:	Drug sales revenues for ZESTRIL
What excipients (inactive ingredients) are in ZESTRIL?	ZESTRIL excipients list
DailyMed Link:	ZESTRIL at DailyMed

See drug prices for ZESTRIL

See drug sales revenues for ZESTRIL

Recent Clinical Trials for ZESTRIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pharmtechnology LLC	Phase 1
ClinPharmInvest, LLC	Phase 1
St. Jude Children's Research Hospital	Phase 2

See all ZESTRIL clinical trials

Pharmacology for ZESTRIL

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors

US Patents and Regulatory Information for ZESTRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-005	Apr 29, 1993	AB	RX	Yes	No
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-003	May 19, 1988	AB	RX	Yes	No
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-001	May 19, 1988	AB	RX	Yes	No
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-002	May 19, 1988	AB	RX	Yes	No

Expired US Patents for ZESTRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-006	Jan 20, 1999	4,374,829*PED
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-005	Apr 29, 1993	4,374,829*PED
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-004	May 19, 1988	4,374,829*PED
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-003	May 19, 1988	4,374,829*PED

International Patents for ZESTRIL

See the table below for patents covering ZESTRIL around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1275349	DERIVES D'ACIDE AMINIQUE (AMINO ACID DERIVATIVES)
Zimbabwe	24479	AMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES
Slovenia	7913000	PROCESS FOR OBTAINING DERIVATIVES OF CARBOXYALKYLDIPEPTIDES
Morocco	18664

ZESTRIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Lisinopril (Zestril)

Introduction to Lisinopril (Zestril)

Lisinopril, commonly known by its brand name Zestril, is an angiotensin-converting enzyme (ACE) inhibitor primarily used to treat high blood pressure, heart failure, and other cardiovascular conditions. Here, we delve into the market dynamics and financial trajectory of lisinopril.

Market Size and Growth

The lisinopril market has been experiencing steady growth, driven by several key factors. As of 2023, the global lisinopril market size was valued at approximately USD 1.5 billion[1][4][5].

• Forecast Period: The market is expected to grow at a compound annual growth rate (CAGR) of around 4.8% to 6.4% from 2024 to 2032, depending on the source. This growth will see the market size reach up to USD 2.3 billion by 2032[1][5].

Drivers of Market Growth

Rising Prevalence of Hypertension and Cardiovascular Diseases

The increasing global burden of hypertension and cardiovascular diseases is a primary driver for the lisinopril market. Cardiovascular diseases, such as coronary artery disease (CAD), are leading causes of mortality worldwide, accounting for approximately 17.8 million deaths annually[1].

Generic Versions and Cost-Effectiveness

The availability of generic lisinopril at more affordable prices has significantly enhanced its market penetration. Generic versions offer a cost-effective solution for patients, healthcare providers, and payers, particularly in regions where cost considerations are crucial[4][5].

Innovations in Drug Delivery

Innovations in novel drug delivery systems are reshaping the field of cardiovascular therapeutics. These advancements are critical as they provide enhanced and patient-centric approaches, meeting the rising demand for effective treatments[1].

Aging Population and Lifestyle Changes

An aging population and lifestyle changes, including sedentary lifestyles and unhealthy dietary habits, contribute to the increased demand for antihypertensive medications like lisinopril. This trend is particularly pronounced in aging populations where cardiovascular issues are more prevalent[4][5].

Market Segmentation

By Dosage

• The lisinopril market is divided into tablet and liquid forms. The tablet segment is estimated to account for a significant portion of the market, projected to reach USD 1.9 billion by 2032[1].

By Dosage Strength

• The market is bifurcated into 10 mg, 20 mg, and 25 mg dosage strengths. The 20 mg segment accounted for USD 573.6 million in 2023[1].

By Patient Age Group

• The market is divided into children and adults. The adults segment is expected to dominate, estimated to account for USD 1.8 billion by 2032[1].

By Application

• Lisinopril is used for various applications, including hypertension, heart failure, heart attack, diabetic kidney disease, and others. The hypertension segment is expected to dominate due to the greater usage of lisinopril in controlling hypertension[4].

By Distribution Channel

• The market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is estimated to account for USD 911.1 million by 2032[1].

Regional Analysis

North America

• North America, particularly the U.S., dominates the global lisinopril market due to the high prevalence of hypertension and cardiovascular diseases. The U.S. market accounted for a significant revenue of USD 631.4 million in 2023[1][5].

Asia-Pacific

• The Asia-Pacific region is expected to grow at the highest rate during the forecast period, driven by an increasing geriatric population and growing healthcare expenditure in countries like China, India, and Japan[4][5].

Europe

• Countries such as Germany and the UK are also expected to experience significant growth in the lisinopril market from 2024 to 2032[1].

Middle East and Africa

• Regions like Saudi Arabia are anticipated to witness promising growth due to increasing healthcare needs and expenditure[1].

Financial Performance and Trends

Revenue Growth

• The lisinopril market has shown strong revenue growth, with a projected increase from USD 1.66 billion in 2023 to USD 1.76 billion in 2024, and further to USD 2.26 billion by 2028 at a CAGR of 6.4%[5].

Key Players

• Major pharmaceutical companies, including those that produce branded and generic versions of lisinopril, play a significant role in the market. Companies like AstraZeneca, which has Zestril in its portfolio, have seen strong performance in their cardiovascular product lines[2].

Challenges and Opportunities

Cost-Effectiveness and Generic Competition

• While the availability of generic lisinopril is a driver, it also presents a challenge for branded versions. The cost-effectiveness of generics can reduce the market share of branded products like Zestril[4].

Regulatory Framework

• The regulatory environment can impact the market. For instance, patent challenges and approvals can affect the sales and market share of specific brands[2].

Innovations and Patient Adherence

• Innovations in drug delivery and patient adherence programs offer opportunities for market growth. Enhanced drug delivery systems can improve patient outcomes and increase market demand[1].

Key Takeaways

• The lisinopril market is driven by the rising prevalence of hypertension and cardiovascular diseases.
• Generic versions and cost-effectiveness are significant factors in market growth.
• Innovations in drug delivery and an aging population contribute to the market's expansion.
• North America and Asia-Pacific are key regions driving market growth.
• The market is expected to grow at a CAGR of 4.8% to 6.4% from 2024 to 2032.

FAQs

What is the current market size of the lisinopril market?

The current market size of the lisinopril market was valued at around USD 1.5 billion in 2023[1].

What is the expected CAGR for the lisinopril market from 2024 to 2032?

The lisinopril market is expected to grow at a CAGR of around 4.8% to 6.4% from 2024 to 2032[1][5].

Which region dominates the global lisinopril market?

North America, particularly the U.S., dominates the global lisinopril market due to the high prevalence of hypertension and cardiovascular diseases[1][5].

What are the primary drivers of the lisinopril market?

The primary drivers include the rising prevalence of hypertension and cardiovascular diseases, the availability of generic versions, innovations in drug delivery, and an aging population[1][4][5].

Which dosage strength segment accounts for the largest share in the lisinopril market?

The 20 mg dosage strength segment accounted for USD 573.6 million in 2023 and is expected to remain a significant segment[1].

What is the impact of generic versions on the lisinopril market?

Generic versions of lisinopril enhance market penetration due to their cost-effectiveness, but they also pose a challenge to branded versions like Zestril[4].

Sources

1. Lisinopril Market Size & Share – Trends Report, 2032 - GMI Insights
2. AstraZeneca Annual Report 2005 - AstraZeneca
3. Global Prilide Antihypertensive Drugs Market - Market Research Intellect
4. Global Lisinopril Market – Industry Trends and Forecast to 2031 - Data Bridge Market Research
5. Lisinopril Global Market Report 2024 - GII Research